Autopsy report · NCT03053284

Pasireotide in Hyperinsulinemic Hypoglycemia

“Funding was withdrawn by Sponsor prior to start of study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Montefiore Medical Center

Sponsor type

University, hospital or other

Conditions

Congenital Hyperinsulinism; Insulinoma; Hyperinsulinism

Interventions

Pasireotide 0.6Mg Solution for Injection; Saline Solution

Participants

0

Trials that died the same way

• Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
  “Funding for study was withdrawn” (90% match in meaning)
• Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma
  “Study funding was withdrawn.” (88% match in meaning)
• Community-based Nutrition Program Effectiveness Evaluation in Afghanistan
  “Funding for the study withdrawn by sponsor after baseline data collected” (87% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (86% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.